The melatonergic system in mood and anxiety disorders and the role of agomelatine: Implications for clinical practice

International Journal of Molecular Sciences

Volumn 14, Issue 6, 2013, Pages 12458-12483

  De Berardis, Domenico ^a,b   Marini, Stefano ^a,b   Fornaro, Michele ^c   Srinivasan, Venkataramanujam ^d   Iasevoli, Felice ^e   Tomasetti, Carmine ^e   Valchera, Alessandro ^f   Perna, Giampaolo ^g,h,i   Quera Salva, Maria Antonia ^j   Martinotti, Giovanni ^b   di Giannantonio, Massimo ^b  

^a Psychiatric Service of Diagnosis and Treatment Hospital G Mazzini   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Sri Sathya Sai Medical Educational and Research Foundation   (India)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Hermanas Hospitalarias   (Italy)

^g Hermanas Hospitalarias FoRiPsi Department of Clinical Neurosciences and Villa San Benedetto Menni ^*  (Italy)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ MAASTRICHT UNIVERSITY   (Netherlands)

^j RAYMOND POINCARÉ HOSPITAL   (France)

more..

Author keywords

Agomelatine; Anxiety; Dopamine; Major depression; Melatonergic receptors; Melatonin; Noradrenaline; Serotonin

Indexed keywords

ACETAMIDE DERIVATIVE; AGOMELATINE; MELATONIN;

AFFECT; ANXIETY DISORDERS; BRAIN; CIRCADIAN RHYTHM; CLINICAL PRACTICE; DRUG EFFECTS; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ACETAMIDES; AFFECT; ANXIETY DISORDERS; BRAIN; CIRCADIAN RHYTHM; HUMANS; MELATONIN; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84890869671     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140612458     Document Type: Review

References (151)

1. Wurtman, R.J.; Larin, F.; Axelrod, J.; Shein, H.M.; Rosasco, K. Formation of melatonin and 5-hydroxyindole acetic acid from 14C-tryptophan by rat pineal glands in organ culture. Nature 1968, 217, 953-954.
2. Cardinali, D.P.; Pévet, P. Basic aspects of melatonin action. Sleep. Med. Rev. 1998, 2, 175-190.
3. Hardeland, R.; Cardinali, D.P.; Srinivasan, V.; Spence, D.W.; Brown, G.M.; Pandi-Perumal, S.R. Melatonin-A pleiotropic, orchestrating regulator molecule. Prog. Neurobiol. 2011, 93, 350-384.
4. Pévet, P. Melatonin. Dialogues Clin. Neurosci. 2002, 4, 57-72.
5. Stehle, J.H.; von Gall, C.; Korf, H.W. Melatonin: A clock-output, a clock-input. J. Neuroendocrinol. 2003, 15, 383-389.
6. Hardeland, R. Melatonin metabolism in the central nervous system. Curr. Neuropharmacol. 2010, 8, 168-181.
7. Dubocovich, M.L.; Markowska, M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005, 27, 101-110.
8. Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; Henlin, J.M.; Lefoulon, F.; Fauchere, J.L.; Delagrange, P.; Canet, E.; Boutin, J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 2000, 275, 31311-31317.
9. Ferry, G.; Hecht, S.; Berger, S.; Moulharat, N.; Coge, F.; Guillaumet, G.; Leclerc, V.; Yous, S.; Delagrange, P.; Boutin, J.A. Old and new inhibitors of quinone reductase 2. Chem. Biol. Interact. 2010, 186, 103-109.
10. Macias, M.; Escames, G.; Leon, J.; Coto, A.; Sbihi, Y.; Osuna, A.; Acuna-Castroviejo, D. Calreticulin-melatonin. An unexpected relationship. Eur. J. Biochem. 2003, 270, 832-840.
11. Benitez-King, G. Melatonin as a cytoskeletal modulator: Implications for cell physiology and disease. J. Pineal Res. 2006, 40, 1-9.
12. Carrillo-Vico, A.; Guerrero, J.M.; Lardone, P.J.; Reiter, R.J. A review of the multiple actions of melatonin on the immune system. Endocrine 2005, 27, 189-200.
13. Hardeland, R. Melatonin: Signaling mechanisms of a pleiotropic agent. Biofactors 2009, 35, 183-192.
14. Wu, Y.H.; Zhou, J.N.; Balesar, R.; Unmehopa, U.; Bao, A.; Jockers, R.; van Heerikhuize, J.; Swaab, D.F. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: Colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone. J. Comp. Neurol. 2006, 499, 897-910.
15. Brunner, P.; Sozer-Topcular, N.; Jockers, R.; Ravid, R.; Angeloni, D.; Fraschini, F.; Eckert, A.; Muller-Spahn, F.; Savaskan, E. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. Eur. J. Histochem. 2006, 50, 311-316.
16. Masson-Pevet, M.; Gauer, F.; Schuster, C.; Guerrero, H.Y. Photic regulation of mt(1) melatonin receptors and 2-iodomelatonin binding in the rat and Siberian hamster. Biol. Signals Recept. 2000, 9, 188-196.
17. Masana, M.I.; Benloucif, S.; Dubocovich, M.L. Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J. Pineal Res. 2000, 28, 185-192.
18. Brydon, L.; Roka, F.; Petit, L.; de Coppet, P.; Tissot, M.; Barrett, P.; Morgan, P.J.; Nanoff, C.; Strosberg, A.D.; Jockers, R. Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol. Endocrinol. 1999, 13, 2025-2038.
19. Schuster, C.; Williams, L.M.; Morris, A.; Morgan, P.J.; Barrett, P. The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J. Neuroendocrinol. 2005, 17, 170-178.
20. Jones, M.P.; Melan, M.A.; Witt-Enderby, P.A. Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner. Cancer Lett. 2000, 151, 133-143.
21. Rimler, A.; Jockers, R.; Lupowitz, Z.; Zisapel, N. Gi and RGS proteins provide biochemical control of androgen receptor nuclear exclusion. J. Mol. Neurosci. 2007, 31, 1-12.
22. Boutin, J.A.; Audinot, V.; Ferry, G.; Delagrange, P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol. Sci. 2005, 26, 412-419.
23. Roka, F.; Brydon, L.; Waldhoer, M.; Strosberg, A.D.; Freissmuth, M.; Jockers, R.; Nanoff, C. Tight association of the human Mel(1a)-melatonin receptor and G(i): Precoupling and constitutive activity. Mol. Pharmacol. 1999, 56, 1014-1024.
24. Brown, T.M.; Piggins, H.D. Electrophysiology of the suprachiasmatic circadian clock. Prog. Neurobiol. 2007, 82, 229-255.
25. Liu, C.; Weaver, D.R.; Jin, X.; Shearman, L.P.; Pieschl, R.L.; Gribkoff, V.K.; Reppert, S.M. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997, 19, 91-102.
26. Gerdin, M.J.; Masana, M.I.; Rivera-Bermudez, M.A.; Hudson, R.L.; Earnest, D.J.; Gillette, M.U.; Dubocovich, M.L. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: Relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J. 2004, 18, 1646-1656.
27. Roy, D.; Angelini, N.L.; Fujieda, H.; Brown, G.M.; Belsham, D.D. Cyclical regulation of GnRH gene expression in GT1-7 GnRH-secreting neurons by melatonin. Endocrinology 2001, 142, 4711-4720.
28. Witt-Enderby, P.A.; Jarzynka, M.J.; Krawitt, B.J.; Melan, M.A. Knock-down of RGS4 and β-tubulin in CHO cells expressing the human MT1 melatonin receptor prevents melatonin-induced receptor desensitization. Life Sci. 2004, 75, 2703-2715.
29. Jarzynka, M.J.; Passey, D.K.; Ignatius, P.F.; Melan, M.A.; Radio, N.M.; Jockers, R.; Rasenick, M.M.; Brydon, L.; Witt-Enderby, P.A. Modulation of melatonin receptors and G-protein function by microtubules. J. Pineal Res. 2006, 41, 324-336.
30. Musshoff, U.; Riewenherm, D.; Berger, E.; Fauteck, J.D.; Speckmann, E.J. Melatonin receptors in rat hippocampus: Molecular and functional investigations. Hippocampus 2002, 12, 165-173.
31. Wang, L.M.; Suthana, N.A.; Chaudhury, D.; Weaver, D.R.; Colwell, C.S. Melatonin inhibits hippocampal long-term potentiation. Eur. J. Neurosci. 2005, 22, 2231-2237.
32. Larson, J.; Jessen, R.E.; Uz, T.; Arslan, A.D.; Kurtuncu, M.; Imbesi, M.; Manev, H. Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci. Lett. 2006, 393, 23-26.
33. Conboy, L.; Tanrikut, C.; Zoladz, P.R.; Campbell, A.M.; Park, C.R.; Gabriel, C.; Mocaër, E.; Sandi, C.; Diamond, D.M. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int. J. Neuropsychopharmacol. 2009, 12, 329-341.
34. Bertaina-Anglade, V.; Drieu-La-Rochelle, C.; Mocaër, E.; Seguin, L. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol. Biochem. Behav. 2011, 98, 511-517.
35. Dubocovich, M.L.; Rivera-Bermudez, M.A.; Gerdin, M.J.; Masana, M.I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci. 2003, 8, d1093-d1108.
36. Fuller, P.M.; Gooley, J.J.; Saper, C.B. Neurobiology of the sleep-wake cycle: Sleep architecture, circadian regulation, and regulatory feedback. J. Biol. Rhythms. 2006, 21, 482-493.
37. Jan, J.E.; Reiter, R.J.; Wasdell, M.B.; Bax, M. The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. J. Pineal Res. 2009, 46, 1-7.
38. Ochoa Sanchez, R.; Comai, S.; Lacoste, B.; Bambico, F.R.; Lopez-Dominguez, S.; Rivara S.; Mor, M.; Bedini, A.L.; Spadoni, G.; Fraschini, F.; et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J. Neurosci. 2011, 14, 18439-18452.
39. Ochoa Sanchez, R.; Comai, S.; Rainer, Q.; Rivara, S.; Mor, M.; Bedini, A.L.; Spadoni, G.; Fraschini, F.; Tarzia, G.; Gobbi, G. Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. Prog. Neuropsychopharmacol. Biol. Psychiatr. 2012, 39, 318-325.
40. Comai, S.; Ochoa-Sanchez, R.; Gobbi, G. Sleep-wake characterization of double MT1 and MT2 receptor knockout mice and comparison with MT1 and MT2 receptor knockout mice. Behav. Brain Res. 2013, 243, 231-238.
41. Reiter, R.J. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 1991, 12, 151-180.
42. Esteban, S.; Garau, C.; Aparicio, S.; Moranta, D.; Barcelo, P.; Fiol, M.A.; Rial, R. Chronic melatonin treatment and its precursor L-tryptophan improve the monoaminergic neurotransmission and related behavior in the aged rat brain. J. Pineal Res. 2010, 48, 170-177.
43. Jiang, Z.G.; Teshima, K.; Yang, Y.; Yoshioka, T.; Allen, C.N. Pre-and postsynaptic actions of serotonin on rat suprachiasmatic nucleus neurons. Brain Res. 2000, 866, 247-256.
44. Morin, L.P. Serotonin and the regulation of mammalian circadian rhythmicity. Ann. Med. 1999, 31, 12-33.
45. Edgar, D.M.; Miller, J.D.; Prosser, R.A.; Dean, R.R.; Dement, W.C. Serotonin and the mammalian circadian system: II. Phase-shifting rat behavioral rhythms with serotonergic agonists. J. Biol. Rhythms 1993, 8, 17-31.
46. + channel opening. Brain Res. 1994, 644, 67-73.
47. Prosser, R.A.; Lee, H.M.; Wehner, A. Serotonergic pre-treatments block in vitro serotonergic phase shifts of the mouse suprachiasmatic nucleus circadian clock. Neuroscience 2006, 142, 547-555.
48. Meyer-Bernstein, E.L.; Morin, L.P. Differential serotonergic innervation of the suprachiasmatic nucleus and the intergeniculate leaflet and its role in circadian rhythm modulation. J. Neurosci. 1996, 16, 2097-2111.
49. Yan, L.; Takekida, S.; Shigeyoshi, Y.; Okamura, H. Per1 and Per2 gene expression in the rat suprachiasmatic nucleus: Circadian profile and the compartment-specific response to light. Neuroscience 1999, 94, 141-150.
50. Caldelas, I.; Challet, E.; Saboureau, M.; Pevet, P. Light and melatonin inhibit in vivo serotonergic phase advances without altering serotonergic-induced decrease of per expression in the hamster suprachiasmatic nucleus. J. Mol. Neurosci. 2005, 25, 53-63.
51. Mendoza, J.; Clesse, D.; Pevet, P.; Challet, E. Serotonergic potentiation of dark pulse-induced phase-shifting effects at midday in hamsters. J. Neurochem. 2008, 106, 1404-1414.
52. Gannon, R.L.; Millan, M.J. Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms. Psychopharmacology 2007, 195, 325-332.
53. Cuesta, M.; Clesse, D.; Pevet, P.; Challet, E. New light on the serotonergic paradox in the rat circadian system. J. Neurochem. 2009, 110, 231-243.
54. Ciarleglio, C.M.; Resuehr, H.E.; McMahon, D.G. Interactions of the serotonin and circadian systems: Nature and nurture in rhythms and blues. Neuroscience 2011, 197, 8-16.
55. Dominguez-Lopez, S.; Mahar, I.; Bambico, F.R.; Labonte, B.; Ochoa-Sanchez, R.; Leyton, M.; Gobbi, G. Short-term effects of melatonin and pinealectomy on serotonergic neuronal activity across the light-dark cycle. J. Psychopharmacol. 2012, 26, 830-844.
56. Klein, D.C.; Coon, S.L.; Roseboom, P.H.; Weller, J.L.; Bernard, M.; Gastel, J.A.; Zatz, M.; Iuvone, P.M.; Rodriguez, I.R.; Begay, V.; et al. The melatonin rhythm-generating enzyme: Molecular regulation of serotonin N-acetyltransferase in the pineal gland. Recent. Prog. Horm. Res. 1997, 52, 307-357; discussion 357-308.
57. Maronde, E.; Saade, A.; Ackermann, K.; Goubran-Botros, H.; Pagan, C.; Bux, R.; Bourgeron, T.; Dehghani, F.; Stehle, J.H. Dynamics in enzymatic protein complexes offer a novel principle for the regulation of melatonin synthesis in the human pineal gland. J. Pineal Res. 2011, 51, 145-155.
58. Ho, A.K.; Mackova, M.; Price, L.; Chik, C.L. Diurnal variation in p42/44 mitogen-activated protein kinase in the rat pineal gland. Mol. Cell. Endocrinol. 2003, 208, 23-30.
59. Ho, A.K.; Chik, C.L. Modulation of Aanat gene transcription in the rat pineal gland. J. Neurochem. 2010, 112, 321-331.
60. Moller, M.; Liu, W. Innervation of the rat pineal gland by nerve fibres originating in the sphenopalatine, otic and trigeminal ganglia. A retrograde in vivo neuronal tracing study. Reprod. Nutr. Dev. 1999, 39, 345-353.
61. Moller, M.; Phansuwan-Pujito, P.; Govitrapong, P.; Schmidt, P. Indications for a central innervation of the bovine pineal gland with substance P-immunoreactive nerve fibers. Brain Res. 1993, 611, 347-351.
62. Mukda, S.; Chetsawang, B.; Govitrapong, P.; Schmidt, P.T.; Hay-Schmidt, A.; Moller, M. Tachykinins and tachykinin-receptors in the rat pineal gland. Eur. J. Neurosci. 2005, 21, 2743-2751.
63. Mukda, S.; Moller, M.; Ebadi, M.; Govitrapong, P. The modulatory effect of substance P on rat pineal norepinephrine release and melatonin secretion. Neurosci. Lett. 2009, 461, 258-261.
64. Koch, M.; Dehghani, F.; Habazettl, I.; Schomerus, C.; Korf, H.W. Cannabinoids attenuate norepinephrine-induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N-acetyltransferase activity without involvement of cannabinoid receptors. J. Neurochem. 2006, 98, 267-278.
65. Koch, M.; Habazettl, I.; Dehghani, F.; Korf, H.W. The rat pineal gland comprises an endocannabinoid system. J. Pineal Res. 2008, 45, 351-360.
66. Garcia, R.A.; Afeche, S.C.; Scialfa, J.H.; do Amaral, F.G.; dos Santos, S.H.; Lima, F.B.; Young, M.E.; Cipolla-Neto, J. Insulin modulates norepinephrine-mediated melatonin synthesis in cultured rat pineal gland. Life Sci. 2008, 82, 108-114.
67. Bailey, M.J.; Coon, S.L.; Carter, D.A.; Humphries, A.; Kim, J.S.; Shi, Q.; Gaildrat, P.; Morin, F.; Ganguly, S.; Hogenesch, J.B.; et al. Night/day changes in pineal expression of >600 genes: Central role of adrenergic/cAMP signaling. J. Biol. Chem. 2009, 284, 7606-7622.
68. Kim, J.S.; Bailey, M.J.; Weller, J.L.; Sugden, D.; Rath, M.F.; Moller, M.; Klein, D.C. Thyroid hormone and adrenergic signaling interact to control pineal expression of the dopamine receptor D4 gene (Drd4). Mol. Cell. Endocrinol. 2010, 314, 128-135.
69. Gonzalez, S.; Moreno-Delgado, D.; Moreno, E.; Perez-Capote, K.; Franco, R.; Mallol, J.; Cortes, A.; Casado, V.; Lluis, C.; Ortiz, J.; et al. Circadian-related heteromerization of adrenergic and dopamine D(4) receptors modulates melatonin synthesis and release in the pineal gland. PLoS Biol. 2012, 10, e1001347.
70. Zisapel, N.; Egozi, Y.; Laudon, M. Inhibition of dopamine release by melatonin: Regional distribution in the rat brain. Brain Res. 1982, 246, 161-163.
71. Alexiuk, N.A.; Uddin, M.; Vriend, J. Melatonin increases the in situ activity of tyrosine hydroxylase in the mediobasal hypothalamus of male Syrian hamsters. Life Sci. 1996, 59, 687-694.
72. Escames, G.; Acuna Castroviejo, D.; Vives, F. Melatonin-dopamine interaction in the striatal projection area of sensorimotor cortex in the rat. Neuroreport 1996, 7, 597-600.
73. Di Chiara, G.; Morelli, M.; Consolo, S. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci. 1994, 17, 228-233.
74. Hamdi, A. Melatonin administration increases the affinity of D2 dopamine receptors in the rat striatum. Life Sci. 1998, 63, 2115-2120.
75. Iuvone, P.M.; Gan, J. Functional interaction of melatonin receptors and D1 dopamine receptors in cultured chick retinal neurons. J. Neurosci. 1995, 15, 2179-2185.
76. Al-Ghoul, W.M.; Herman, M.D.; Dubocovich, M.L. Melatonin receptor subtype expression in human cerebellum. Neuroreport 1998, 9, 4063-4068.
77. Poirel, V.J.; Cailotto, C.; Streicher, D.; Pevet, P.; Masson-Pevet, M.; Gauer, F. MT1 melatonin receptor mRNA tissular localization by PCR amplification. Neuro Endocrinol. Lett. 2003, 24, 33-38.
78. Mazzucchelli, C.; Pannacci, M.; Nonno, R.; Lucini, V.; Fraschini, F.; Stankov, B.M. The melatonin receptor in the human brain: Cloning experiments and distribution studies. Brain Res. Mol. Brain Res. 1996, 39, 117-126.
79. Kurtuncu, M.; Arslan, A.D.; Akhisaroglu, M.; Manev, H.; Uz, T. Involvement of the pineal gland in diurnal cocaine reward in mice. Eur J. Pharmacol. 2004, 489, 203-205.
80. Sircar, R. Effect of melatonin on cocaine-induced behavioral sensitization. Brain Res. 2000, 857, 295-299.
81. Imbesi, M.; Uz, T.; Yildiz, S.; Arslan, A.D.; Manev, H. Drug-and region-specific effects of protracted antidepressant and cocaine treatment on the content of melatonin MT(1) and MT(2) receptor mRNA in the mouse brain. Int. J. Neuroprot. Neuroregener. 2006, 2, 185-189.
82. Sharma, R.; McMillan, C.R.; Niles, L.P. Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease. J. Pineal Res. 2007, 43, 245-254.
83. Lin, C.H.; Huang, J.Y.; Ching, C.H.; Chuang, J.I. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J. Pineal Res. 2008, 44, 205-213.
84. Lai, I.C.; Chen, M.L.; Wang, Y.C.; Chen, J.Y.; Liao, D.L.; Bai, Y.M.; Lin, C.C.; Chen, T.T.; Liou, Y.J. Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia. World J. Biol. Psychiatr. 2011, 12, 143-148.
85. Courtet, P.; Olié, E. Circadian dimension and severity of depression. Eur. Neuropsychopharmacol. 2012, 22, S476-S481.
86. Wirz-Justice, A. Diurnal variation of depressive symptoms. Dialogues Clin. Neurosci. 2008, 10, 337-343.
87. Dallaspezia, S.; Benedetti, F. Chronobiological therapy for mood disorders. Expert Rev. Neurother. 2011, 11, 961-970.
88. Coogan, A.N.; Thome, J. Chronotherapeutics and psychiatry: Setting the clock to relieve the symptoms. World J. Biol. Psychiatr. 2011, 12, 40-43.
89. Barden, N.; Shink, E.; Labbé, M.; Vacher, R.; Rochford, J.; Mocaër, E. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog. Neuropsychopharmacol. Biol. Psychiatr. 2005, 29, 908-916.
90. Leproult, R.; Van Onderbergen, A.; L'hermite-Balériaux, M.; van Cauter, E.; Copinschi, G. Phase-shifts of 24 h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin. Endocrinol. 2005, 63, 298-304.
91. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.; Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J.P.; et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 6, 553-561.
92. Sharpley, A.L.; Rawlings, N.B.; Brain, S.; McTavish, S.F.; Cowen, P.J. Does agomelatine block 5-HT2C receptors in humans? Psychopharmacology 2011, 213, 653-655.
93. Norman, T.R. The effect of agomelatine on 5HT(2C) receptors in humans: A clinically relevant mechanism? Psychopharmacology 2012, 221, 177-178.
94. Millan, M.J.; Gobert, A.; Lejeune, F.; Dekeyne, A.; Newman-Tancredi, A.; Pasteau, V.; Rivet, J.M.; Cussac, D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 2003, 306, 954-964.
95. Dubocovich, M.L. Drug evaluation: Agomelatine targets a range of major depressive disorder symptoms. Curr. Opin. Investig. Drugs 2006, 7, 670-680.
96. Palazidou, E.; Papadopoulos, A.; Ratcliff, H.; Dawling, S.; Checkley, S.A. NE uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients. Psychol. Med. 1992, 22, 309-315.
97. Mitchell, H.A.; Weinshenker, D. Good night and good luck: Norepinephrine in sleep pharmacology. Biochem. Pharmacol. 2009, 79, 801-809.
98. Kripke, D.F.; Youngstedt, S.D.; Rex, K.M.; Klauber, M.R.; Elliott, J.A. Melatonin excretion with affect disorders over age 60. Psychiatr. Res. 2003, 118, 47-54.
99. Carvalho, L.A.; Gorenstein, C.; Moreno, R.A.; Markus, R.P. Melatonin levels in drug-free patients with major depression from the southern hemisphere. Psychoneuroendocrinology 2006, 31, 761-768.
100. Rubin, R.T.; Heist, E.K.; McGeoy, S.S.; Hanada, K.; Lesser, I.M. Neuroendocrine aspects of primary endogenous depression. XI. Serum melatonin measures in patients and matched control subjects. Arch. Gen. Psychiatr. 1992, 49, 558-567.
101. Shafii, M.; MacMillan, D.R.; Key, M.P.; Derrick, A.M.; Kaufman, N.; Nahinsky, I.D. Nocturnal serum melatonin profile in major depression in children and adolescents. Arch. Gen. Psychiatr. 1996, 53, 1009-1013.
102. Sekula, L.K.; Lucke, J.F.; Heist, E.K.; Czambel, R.K.; Rubin, R.T. Neuroendocrine aspects of primary endogenous depression. XV: Mathematical modeling of nocturnal melatonin secretion in major depressives and normal controls. Psychiatr. Res. 1997, 69, 143-153.
103. Crasson, M.; Kjiri, S.; Colin, A.; Kjiri, K.; L'Hermite-Baleriaux, M.; Ansseau, M.; Legros, J.J. Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 2004, 29, 1-12.
104. Wetterberg, L. Clinical importance of melatonin. Prog. Brain Res. 1979, 52, 539-547.
105. Srinivasan, V.; de Berardis, D.; Shillcutt, S.D.; Brzezinski, A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin. Investig. Drugs 2012, 21, 1503-1522.
106. Pompili, M.; Serafini, G.; Innamorati, M.; Venturini, P.; Fusar-Poli, P.; Sher. L.; Amore M.; Girardi, P. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review. World J. Biol. Psychiatr. 2013, in press.
107. Dagytė, G.; Crescente, I.; Postema, F.; Seguin, L.; Gabriel, C.; Mocaër, E.; Boer, J.A.; Koolhaas, J.M. Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress. Behav. Brain Res. 2011, 218, 121-128.
108. Tardito, D.; Molteni, R.; Popoli, M.; Racagni, G. Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur. Neuropsychopharmacol. 2012, 22, 482-486.
109. San, L.; Arranz, B. Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur. Psychiatr. 2008, 23, 396-402.
110. European Medicines Agency. Evaluation of Medicines for Human Use CHMP Assessment Report for Valdoxan. Available online: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ valdoxan/H-915-en6.pdf (accessed on 26 December 2009).
111. Servier Laboratories Ltd. Valdoxan (agomelatine) Summary of Product Characteristics, 2009. Available online: http://emc. medicines.org.uk/medicine/21830/SPC/Valdoxan/ (accessed on 29 January 2010).
112. Dolder, C.R.; Nelson, M.; Snider, M. Agomelatine treatment of major depressive disorder. Ann. Pharmacother. 2008, 42, 1822-1831.
113. Sadock, B.J.; Sadock, V.A. Kaplan Sadock's Synopsis of Psychiatry: Behavioral Sciences; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2005.
114. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatr. 2005, 62, 593-602.
115. Kessler, R.C.; Chiu, W.T.; Demler, O.; Merikangas, K.R.; Walters, E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatr. 2005, 62, 617-627.
116. De Berardis, D.; Serroni, N.; Campanella, D.; Carano, A.; Gambi, F.; Valchera, A.; Conti, C.; Sepede, G.; Scali, M.; Fulcheri, M.; et al. Alexithymia and its relationships with C-reactive protein and serum lipid levels among drug naïve adult outpatients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatr. 2008, 32, 1982-1986.
117. Murray, C.J.; Lopez, A.D. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997, 349, 1498-1504.
118. Lopez, A.D.; Mathers, C.D.; Ezzati, M.; Jamison, D.T.; Murray, C.J. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006, 367, 1747-1757.
119. Fava, M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatr. 2003, 15, 649-659.
120. Little, A. Treatment-resistant depression. Am. Fam. Physician 2009, 80, 167-172.
121. Parker, G.; Brotchie, H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr. Scand. 2009, 121, 308-314.
122. Hickie, I. Is depression overdiagnosed? No. BMJ 2007, 335, 329.
123. Hall, W.D.; Mant, A.; Mitchell, P.B.; Rendle, V.A.; Hickie, I.B.; McManus, P. Association between antidepressant prescribing and suicide in Australia, 1991-2000: Trend analysis. BMJ 2003, 326, 1008.
124. Loo, H.; Hale, A.; D'Haenen, H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: A placebo-controlled dose range study. Int. Clin. Psychopharmacol. 2002, 17, 239-247.
125. Kennedy, S.H.; Emsley, R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. 2006, 16, 93-100.
126. Olie, J.P.; Kasper, S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Neuropsychopharmacol. 2007, 10, 661-673.
127. Lemoine, P.; Guilleminault, C.; Alvarez, E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatr. 2007, 68, 1723-1732.
128. Martinotti, G.; Sepede, G.; Gambi, F.; di Iorio, G.; de Berardis, D.; di Nicola, M.; Onofrj, M.; Janiri, L.; di Giannantonio, M. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: A pilot study. J. Clin. Psychopharmacol. 2012, 32, 487-491.
129. Kennedy, S.H.; Rizvi, S.; Fulton, K.; Rasmussen, J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J. Clin. Psychopharmacol. 2008, 28, 329-333.
130. Kasper, S.; Hajak, G.; Wulff, K.; Hoogendijk, W.J.; Montejo, A.L.; Smeraldi, E.; Rybakowski, J.K.; Quera-Salva, M.A.; Wirz-Justice, A.M.; Picarel-Blanchot, F.; et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. J. Clin. Psychiatr. 2010, 71, 109-120.
131. Hale, A.; Corral, R.M.; Mencacci, C.; Ruiz, J.S.; Severo, C.A.; Gentil, V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: A randomized, double-blind study. Int. Clin. Psychopharmacol. 2010, 25, 305-314.
132. Quera-Salva, M.A.; Hajak, G.; Philip, P.; Montplaisir, J.; Keufer-Le Gall, S.; Laredo, J.; Guilleminault, C. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int. Clin. Psychopharmacol. 2011, 26, 252-262.
133. Karaiskos, D.; Tzavellas, E.; Ilias, I.; Liappas, I.; Paparrigopoulos, T. Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus. Int. J. Clin. Pract. 2013, 67, 257-260.
134. Spijker, J.; Bijl, R.V.; de Graaf, R.; Nolen, W.A. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: Results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr. Scand. 2001, 103, 122-130.
135. Taylor, D.J.; Walters, H.M.; Vittengl, J.R.; Krebaum, S.; Jarret, R.B. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence? J. Affect. Disord. 2010, 123, 181-187.
136. Keedwell, P.A.; Andrew, C.; Williams, S.C.; Brammer, M.J.; Phillips, M.L. The neural correlates of anhedonia in major depressive disorder. Biol. Psychiatr. 2005, 58, 843-853.
137. Di Giannantonio, M.; Martinotti, G. Anhedonia and major depression: The role of agomelatine. Eur. Neuropsychopharmacol. 2012, 22, 505-510.
138. Di Giannantonio, M.; di Iorio, G.; Guglielmo, R.; de Berardis, D.; Conti, C.M.; Acciavatti, T.; Cornelio, M.; Martinotti, G. Major depressive disorder, anhedonia and agomelatine: An open-label study. J. Biol. Regul. Homeost. Agents 2011, 25, 109-114.
139. Quera Salva, M.A.; Vanier, B.; Laredo, J.; Hartley, S.; Chapotot, F.; Moulin, C.; Lofaso, F.; Guilleminault, C. Major depressive disorder, sleep EEG and agomelatine: An open-label study. Int. J. Neuropsychopharmacol. 2007, 10, 691-696.
140. Lopes, M.C.; Quera-Salva, M.A.; Guilleminault, C. Non-REM sleep instability in patients with major depressive disorder: Subjective improvement and improvement of non-REM sleep instability with treatment (agomelatine). Sleep Med. 2007, 9, 33-41.
141. Montejo, A.; Prieto, N.; Terleira, A.; Matias, J.; Alonso, S.; Paniagua, G.; Naval, S.; Parra, D.G.; Gabriel, C.; Mocaër, E.; et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers: An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J. Psychopharmacol. 2010, 24, 111-120.
142. Montgomery, S.A.; Kennedy, S.H.; Burrows, G.D.; Lejoyeux, M.; Hindmarch, I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol. 2004, 19, 271-280.
143. Sparshatt, A.; McAllister Williams, R.H.; Baldwin, D.S.; Haddad, P.M.; Bazire, S.; Weston, E.; Taylor, P.; Taylor, D. A naturalistic evaluation and audit database of agomelatine: Clinical outcome at 12 weeks. Acta Psychiatr. Scand. 2012, in press.
144. Goodwin, G.; Emsley, R.; Rembry, S.; Rouillon, F. Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder, without evidence of a discontinuation syndrome. J. Clin. Psychiatr. 2009, 70, 1128-1237.
145. Servier Laboratories. Valdoxan. Available online: http://www.valdoxan.com/index.php/ valdoxan-package-leaflet-information-for the-user (accessed on 3 May 2011).
146. Zajecka, J.; Schatzberg, A.; Stahl, S.; Shah, A.; Caputo, A.; Post, A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2010, 30, 135-144.
147. Stahl, S.M.; Fava, M.; Trivedi, M.H.; Caputo, A.; Shah, A.; Post, A. Agomelatine in the treatmentof major depressive disorder: An 8-week, multicenter, randomized, placebo-controlled trial. J. Clin. Psychiatr. 2010, 71, 616-626.
148. European Medicines Agency. CHMP Assessment Report for Valdoxan. Document Reference EMEA/655251/2008. European Medicines Agency: London, UK, 2008.
149. De Berardis, D.; di Iorio, G.; Acciavatti, T.; Conti, C.; Serroni, N.; Olivieri, L.; Cavuto, M.; Martinotti, G.; Janiri, L.; Moschetta, F.S.; et al. The emerging role of melatonin agonists in the treatment of major depression: Focus on agomelatine. CNS Neurol. Disord. Drug Targets 2011, 10,119-132.
150. Howland, R.H. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011, 34, 709-731.
151. Howland, R.H. Publication bias and outcome reporting bias: Agomelatine as a case example. J. Psychosoc. Nurs. Ment. Health Serv. 2011, 49, 11-14.